Similar articles

• The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.

  Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Díez O, Alonso MC, Lazaro C, Blanco I, Sánchez-de-Abajo A, Caldés T, Blanco A, Graña B, Durán M, Velasco E, Chirivella I, Cardeñosa EE, Tejada MI, Beristain E, Miramar MD, Calvo MT, Martínez E, Guillén C, Salazar R, San Román C, Antoniou AC, Urioste M, Benítez J. Milne RL, et al. Clin Cancer Res. 2008 May 1;14(9):2861-9. doi: 10.1158/1078-0432.CCR-07-4436. Clin Cancer Res. 2008. PMID: 18451254
• Cancer. A risky business--assessing breast cancer risk.

  Levy-Lahad E, Plon SE. Levy-Lahad E, et al. Science. 2003 Oct 24;302(5645):574-5. doi: 10.1126/science.1091465. Science. 2003. PMID: 14576407 No abstract available.
• BRCA1 and BRCA2 cancer risks.

  Antoniou AC, Pharoah PD, Easton DF, Evans DG. Antoniou AC, et al. J Clin Oncol. 2006 Jul 10;24(20):3312-3; author reply 3313-4. doi: 10.1200/JCO.2006.06.7934. J Clin Oncol. 2006. PMID: 16829658 No abstract available.
• Genomic rearrangements in the BRCA1 and BRCA2 genes.

  Mazoyer S. Mazoyer S. Hum Mutat. 2005 May;25(5):415-22. doi: 10.1002/humu.20169. Hum Mutat. 2005. PMID: 15832305 Review.
• Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.

  Wolff TA, Wilson JE. Wolff TA, et al. Am Fam Physician. 2006 Nov 15;74(10):1759-60. Am Fam Physician. 2006. PMID: 17137007 Review. No abstract available.